房颤患者超说明书减量NOAC的安全性
基于英国CPRD的队列研究比较房颤患者超说明书减量NOAC与按说明书标准剂量的结局。超说明书减量者卒中和大出血风险与标准剂量者相似,非大出血风险较低但死亡率较高,提示超说明书减量需谨慎。
要点
- 超说明书减量NOAC者卒中及大出血风险与标准剂量者相似。
- 超说明书减量者非大出血风险较低但死亡率较高。
- 处方超说明书减量NOAC需谨慎。
核心结论
- 房颤患者超说明书减量NOAC与按说明书标准剂量相比,卒中和大出血风险低且相似,非大出血风险较低但死亡风险较高,需谨慎处方超说明书减量。
研究设计与样本
- 基于英国临床实践研究数据链(CPRD)的 population-based 队列研究,比较非瓣膜性房颤成人中接受超说明书减量NOAC者与按说明书标准剂量者的结局。
- 采用倾向评分逆概率治疗加权和逆概率删失加权调整混杂和信息性删失。
主要发现
- 超说明书减量组中位年龄80岁(IQR 73.0-86.0),标准剂量组72岁(IQR 66-78)。
- 超说明书减量组较标准剂量组发生率更高:缺血性卒中0.94 vs 0.70/100人年,大出血1.48 vs 0.83,非大出血6.78 vs 6.16,死亡10.12 vs 3.72。
- 调整后风险比:缺血性卒中0.95(95%CI 0.57-1.60),大出血0.88(95%CI 0.57-1.35),非大出血0.81(95%CI 0.67-0.98),死亡1.34(95%CI 1.12-1.61)。
关键数值与推荐
- 超说明书减量NOAC与标准剂量比较:缺血性卒中HR 0.95(95%CI 0.57-1.60),大出血HR 0.88(95%CI 0.57-1.35),非大出血HR 0.81(95%CI 0.67-0.98),死亡HR 1.34(95%CI 1.12-1.61)。
临床怎么用
- 房颤患者处方NOAC时应严格按说明书标准剂量,超说明书减量需谨慎评估,尤其关注死亡风险升高信号。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To investigate the effects of off-label non-vitamin K oral anticoagulant (NOAC) dose reduction compared with on-label standard dosing in atrial fibrillation (AF) patients in routine care. METHODS: Population-based cohort study using data from the United Kingdom Clinical Practice Research Datalink, comparing adults with non-valvular AF receiving an off-label reduced NOAC dose to patients receiving an on-label standard dose. Outcomes were ischaemic stroke, major/non-major bleeding and mortality. Inverse probability of treatment weighting and inverse probability of censoring weighting on the propensity score were applied to adjust for confounding and informative censoring. RESULTS: Off-label dose reduction occurred in 2466 patients (8.0%), compared with 18 108 (58.5%) on-label standard-dose users. Median age was 80 years (interquartile range [IQR] 73.0-86.0) versus 72 years (IQR 66-78), respectively. Incidence rates were higher in the off-label dose reduction group compared to the on-label standard dose group, for ischaemic stroke (0.94 vs 0.70 per 100 person years), major bleeding (1.48 vs 0.83), non-major bleeding (6.78 vs 6.16) and mortality (10.12 vs 3.72). Adjusted analyses resulted in a hazard ratio of 0.95 (95% confidence interval [CI] 0.57-1.60) for ischaemic stroke, 0.88 (95% CI 0.57-1.35) for major bleeding, 0.81 (95% CI 0.67-0.98) for non-major bleeding and 1.34 (95% CI 1.12-1.61) for mortality. CONCLUSION: In this large population-based study, the hazards for ischaemic stroke and major bleeding were low, and similar in AF patients receiving an off-label reduced NOAC dose compared with on-label standard dose users, while non-major bleeding risk appeared to be lower and mortality risk higher. Caution towards prescribing an off-label reduced NOAC dose is therefore required.
引用
- van den Dries CJ, Pajouheshnia R, van den Ham HA, et al. Safety of off-label dose reduction of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Br J Clin Pharmacol. 2022. PMID: 36102068. doi:10.1111/bcp.15534
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。